Chile's CFR makes $1.3bn bid for Adcock Ingram
This article was originally published in Scrip
Executive Summary
A new pharma powerhouse centered in emerging markets is on the cards as Chilean firm CFR Pharmaceuticals has entered talks with South Africa's Adcock Ingram for a cash and shares deal valuing Adcock Ingram at $1.3bn. The combination of the two firms would create a company with combined revenues of about $1.3bn and particular strength in Latin America and sub-Saharan Africa.